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Abstract
Recent studies have established that a significant
fraction of prostate cancers harbor a signature gene
fusion between the 5V region of androgen-regulated
TMPRSS2 and an ETS family transcription factor, most
commonly ERG. Studies on the molecular mechanisms
and functional consequences of this important chro-
mosomal rearrangement are currently limited to the
VCaP cell line derived from a vertebral bone metastasis
of a hormone-refractory prostate tumor. Here we report
on the NCI-H660 cell line, derived from a metastatic site
of an extrapulmonary small cell carcinoma arising
from the prostate. NCI-H660 harbors TMPRSS2–ERG
fusion with a homozygous intronic deletion between
TMPRSS2 and ERG. We demonstrate this by real-time
quantitative polymerase chain reaction, a two-stage
dual-color interphase fluorescence in situ hybridi-
zation (FISH) assay testing for TMPRSS2 and ERG
break-aparts, and single-nucleotide polymorphism oli-
gonucleotide arrays. The deletion is consistent with
the common intronic deletion found on chromosome
21q22.2–3 in human prostate cancer samples. We
demonstrate the physical juxtaposition of TMPRSS2
and ERG on the DNA level by fiber FISH. The androgen
receptor–negative NCI-H660 cell line expresses ERG in
an androgen-independent fashion. This in vitro model
system has the potential to provide important patho-
biologic insights into TMPRSS2–ERG fusion prostate
cancer.
Neoplasia (2007) 9, 200–206
Keywords: TMPRSS2–ERG, prostate cancer, cell line, gene fusion,
translocation.
Introduction
Recent work demonstrates that nearly half of prostate-specific
antigen (PSA)–screened prostate cancers harbor TMPRSS2-
ETS fusions [1–3]. ERG (21q22.3), ETV1 (7p21.2), or ETV4
(17q21) is activated by a genetic rearrangement that fuses
the 3V end of either gene to the 5V end of androgen-regulated
TMPRSS2 (21q22.2). This generates an androgen-responsive
fusion oncoprotein, leading to overexpression of the respec-
tive ETS family member [1,2]. TMPRSS2-ETS fusion is the
first mechanistic explanation for dominant oncogene activa-
tion in a significant fraction of prostate cancers. TMPRSS2–
ERG fusion is the most common rearrangement, which is
significantly associated with prostate cancer–specific mortality
[4]. Therefore, gene fusion status represents an important
subclassification of prostate cancer from a biologic and a clini-
cal standpoint.
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TMPRSS2–ERG fusion occurs most frequently through
intronic deletion between TMPRSS2 and ERG on 21q22.2–
3 [3]. None of the classic prostate carcinoma cell lines
(DU145, PC3, or LNCaP) harbors TMPRSS2–ETS fu-
sions. Understanding the functional biology of underlying
gene fusion is currently limited to the androgen-dependent
VCaP cell line that was established from the vertebral
bone metastasis of a hormone-refractory prostate tumor
[5]. The VCaP cell line represents an in vitro model for
TMPRSS2–ERG gene fusion but has unusual genomic fea-
tures in that it shows copy number gain on chromosome
21q, which has not been observed in > 300 prostate cancer
samples studied to date [1,3,4]. In addition, VCaP has at
least one normal TMPRSS2 and ERG gene, which makes
it difficult to study TMPRSS2–ERG rearrangement in vitro
in the presence of wild-type copies of both fusion partners.
In VCaP, fusion transcripts encode TMPRSS2 fused to
exon 4 of ERG, corresponding to the ERGa described by
Tomlin et al. [1].
Here we present the androgen-independent NCI-H660
cell line as a novel in vitro model for prostate cancer. NCI-
H660 cells harbor TMPRSS2–ERG gene fusion through a
common intronic deletion on chromosome 21 in homozygous
form.We propose it as a potential cell culture system to study
and manipulate TMPRSS2–ERG fusion in vitro.
Materials and Methods
Cell Lines and Xenografts
The prostate cancer cell lines NCI-H660, PC3, DU145,
LNCaP, 22Rv1, and CA-HPV-10 were purchased from the
American Type Culture Collection (Manassas, VA) and main-
tained according to the provider’s instructions. The VCaP cell
line is derived from a vertebral metastatic lesion as part of
the Rapid Autopsy Program at the University of Michigan
[5]. Normal prostate stromal cells (PrSCs) were obtained
from Cambrex Bio Science (East Rutherford, NJ).
LuCaP 23.1, 35, 49, 58, 73, 81, 86.2, 92.1, 93, 96, and 115
have been established by R.L.V. and have been previously
described [3]. Of note, LuCaP 49 (established from an omen-
tal fat metastasis) and LuCaP 93 are hormone-insensitive
[androgen receptor (AR)–negative] small cell prostate can-
cers with a neuroendocrine phenotype.
Tissue Samples
Lymph node specimens were collected from the radical
prostatectomy series at the University of Ulm (Ulm, Ger-
many) [6]. Hormone-refractory metastatic samples were
part of the Rapid Autopsy Program for prostate cancer
(University of Michigan Specialized Program of Research
Excellence) and consist of histologically confirmed pros-
tatic tumors involving solid organs (e.g., liver and lung) or
distant lymph nodes [7,8]. All samples were collected as
part of institutional review board protocols at each respec-
tive institution.
Polymerase Chain Reaction (PCR) and Real-Time
Quantitative PCR (qPCR) for TMPRSS2–ERG
Fusion Transcripts
We used the following primers for the detection of
TMPRSS2–ERG, as described by Tomlins et al. [1]:
TMPRSS2:ERG_f andTMPRSS2:ERG_r as reverse primers
in ERG exon 4 for real-time qPCR, and exon 5–6_r as re-
verse primer in ERG exon 6 for reverse transcription (RT)
PCR. Exon 5–6_f and exon 5–6_r primers were used for
the detection of ERG. Total RNA was isolated with Trizol
(Invitrogen, Carlsbad, CA) and reverse-transcribed using
TaqMan reverse transcription reagent in the presence
of random hexamers and oligo dT primers (Applied Bio-
systems, Foster City, CA).
RT-PCR amplifications were performed using 30 ng of
cDNA as template in a final volume of 50 ml using the Plati-
num Taq DNA Polymerase kit (Invitrogen) at an annealing
temperature of 63jC. Amplified PCR fragments were cloned
and sequenced as described [9].
For qPCR, the amount of each target gene relative to
GAPDH was determined for each sample using the com-
parative threshold cycle method (Applied Biosystems), as
described [1]. For androgen stimulation experiments, 2
Power SYBR Green Master Mix (Applied Biosystems) and
25 ng of both forward and reverse primers were used for
ERG, PSA, and HMBS [10]. A 2 TaqMan Universal PCR
Master Mix, a final concentration of 900 nM forward and
reverse primers, and a 250-nM probe were used for TaqMan
TMPRSS2–ERGa detection using the following primers and
probe: TM_ERGa forward, CTGGAGCGCGGCAGGAA;
TM_ERGa reverse, CCGTAGGCACACTCAAACAACGA;
TM_ERGa probe, TTATCAGTTGTGAGTGAGGAC.
Determining TMPRSS2–ERG Fusion and Deletion Status
Using a Two-Stage Dual-Color Interphase Fluorescence
In Situ Hybridization (FISH) Assay
To assess the TMPRSS2–ETS fusion status, we applied
a two-stage dual-color break-apart FISH assay. First, we
identified the rearrangement of TMPRSS2. Second, we
tested for ERG break-apart to determine if ERG was the fu-
sion partner for TMPRSS2. The ERG break-apart assay
has been described [3]. The TMPRSS2 break-apart assay
consisted of the biotin-16-dUTP–labeled BAC clone RP11-
662D5 and the digoxigenin-11-dUTP–labeled BAC clone
RP11-260O11. These probes span the neighboring centro-
meric and telomeric regions of the TMPRSS2 locus, respec-
tively. Samples were mounted on Prolong Gold Antifade
Reagent with DAPI (Invitrogen) and analyzed under a 60
oil immersion objective using an Olympus BX-51 (Olympus
America Inc., Center Valley, PA) fluorescence microscope
equipped with appropriate filters, a charge-coupled device
camera, and the CytoVision FISH imaging and capturing
software (Applied Imaging, San Jose, CA).
Fiber FISH
DNA was isolated from f 5  106 cells followed by
24 hours of incubation with 300 ml of Puregene Cell Lysis
Solution (Gentra Systems, Minneapolis, MN). About 10 ml of
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lysed DNA solution was stretched on a poly-L-lysine–coated
slide with a coverslip, followed by fixation in ethanol [11].
The slides were hybridized for 16 hours at 37jC with probes
specific to TMPRSS2 (RP11-120C17 labeled with biotin-
16-dUTP; red) and ERG (RP11-476D17 labeled with
digoxigenin-11-dUTP; green).
Single-Nucleotide Polymorphism (SNP) Array Analysis
Genomic DNA was isolated from a total of 25 samples (cell
lines, punch biopsies of xenografts, lymph nodes, and visceral
organ metastases) according to standard procedures. DNA
was hybridized according to the manufacturer’s protocol
(Affymetrix, Santa Clara, CA) [12], either to Affymetrix 10K or
50K Xba SNP arrays. Arrays were scanned with a GeneChip
Scanner 3000 (Affymetrix). Data were analyzed using the
informatics platform dChipSNP [13]. For each array type,
preprocessing included array data normalization to a baseline
array using a set of invariant probes and subsequent process-
ing to obtain single intensity values for each SNP on each
sample using a model-based (PM/MM) method [14]. We then
merged the datasets on common SNPs (both represented on
the 10K and the 50K arrays), ending with a set off 8K SNPs.
Androgen Stimulation
Treatments with the synthetic androgen R1881 and the
AR antagonist flutamide were performed as described [1].
Results
The NCI-H660 cell line was originally described as a small
cell lung carcinoma [15]. Subsequently, it was correctly iden-
tified as an extrapulmonary small cell carcinoma originating
from the prostate gland [16,17]. The line is derived from a
lymph node metastasis taken from a patient before therapy.
The patient was a 63-year-old white male who was diag-
nosed with extrapulmonary small cell carcinoma in 1983. He
died from this cancer 18 days after the initial diagnosis
and was autopsied with multiple metastatic sites (Bruce E.
Johnson, personal communication, Dana Farber Cancer
Institute, Boston, MA). NCI-H660 has been reported to be
AR-negative by Western blot analysis, and its growth has
been reported to be androgen-independent [18]. When we
tested the NCI-H660 cell line for TMPRSS2–ERG fusion, we
detected two RT-PCR products (Figure 1A). Cloning and
sequencing identified the transcripts as ERGa, a previously
reported fusion type [1], plus an additional isoform con-
taining the first two exons of TMPRSS2, juxtaposed to
exon 4 of ERG (fusion type VI according to Wang et al. [9])
(Figure 1B). The two-sequence verified TMPRSS2–ERG
fusion transcripts in NCI-H660 are identical to the ones found
in human tumor samples [9]. Real-time qPCR demonstrated
expression of TMPRSS2–ERG gene fusion in the NCI-H660
cell line, leading to about a 6000-fold elevated ERG ex-
pression compared to normal PrSCs (Figure 1C). For com-
parison, the VCaP cell line shows about 50,000 times higher
Figure 1. Characterization of TMPRSS2–ERG fusion and ERG expression in the NCI-H660 prostate cancer cell line. (A) RT-PCR using a forward primer in exon 1
of TMPRSS2 and a reverse primer in exon 6 of ERG revealed two transcripts of TMPRSS2–ERG fusion in NCI-H660 (first lane). For comparison, VCaP expressed
only one fusion transcript (second lane), whereas normal PrSCs did not harbor TMPRSS2–ERG fusion (third lane). (B) The identity of the fusion transcripts was
verified by sequencing. The shorter transcript consisted of TMPRSS2 exon 1 (T1) fused to ERG exon 4 (E4). This transcript was also found in the VCaP cell line.
The longer transcript was identified as TMPRSS2 exons 1 and 2 (T1 and T2), fused to ERG exon 4 (E4). Upper panel: sequencing profiles of T1-E4 and T2-E4
transcripts. Lower panel: corresponding schemes of the two fusion types. (C) Real-time qPCR for TMPRSS2–ERG expression (upper panel) and ERG expression
(lower panel) on several cancer cell lines. The standard (PrSCs) was expressed as 1 (dashed line). Orange bars correspond to TMPRSS2–ERG fusion through
deletion in NCI-H660, leading to a f 6  103– fold overexpression of ERG. Green bars correspond to TMPRSS2–ERG fusion in VCaP, leading to a f 5 
104– fold overexpression of ERG. Grey bars correspond to the other prostate cancer cell lines tested (PC3, LNCaP, DU145, and 22Rv1) that do not harbor
TMPRSS2–ERG fusion and show baseline or moderately elevated ERG expression. Meg01 is a leukemia cell line without TMPRSS2–ERG fusion, but with
overexpression of ERG (f 3  103– fold), which served as a positive control for ERG expression.
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Figure 2. Dual-color TMPRSS2 and ERG break-apart FISH assays for the detection of TMPRSS2–ERG fusion in NCI-H660 and VCaP. (A) The scheme of the
dual-color TMPRSS2 and ERG break-apart FISH assays explains the detection of TMPRSS2–ERG fusion. The location of the genes is indicated relative to the
chromosome (boxes); the orientation of the genes is indicated by arrows. C = centromere; E = exon. For both assays, the relative location of differentially labeled
telomeric and centromeric BAC probes is indicated by colored circles, with the color indicating the probe color in (B), (C), (D), and (E), and with the number
identifying the BACs as follows: 1 = RP11-24A11; 2 = RP11-372O17; 3 = RP11-662D5; 4 = RP11-260O11. (B) FISH image of a VCaP interphase nucleus
assessed by dual-color ERG break-apart assay (as illustrated in A). The nucleus contains several juxtaposed red and green signals for amplified wild-type alleles,
and separated red and green signals indicating ERG insertion. (C) FISH image of a VCaP interphase nucleus assessed by dual-color TMPRSS2 break-apart assay
(as illustrated in A). The nucleus contains several juxtaposed red and green signals for amplified wild-type alleles, and separated red and green signals indicating
TMPRSS2 insertion. (D) FISH image of an NCI-H660 interphase nucleus assessed by dual-color ERG break-apart assay (as illustrated in A). The nucleus shows
only two single red centromeric signals but no telomeric green signals. This is indicative of a fusion of TMPRSS2 with ERG through homozygous deletion of the
intergenic region. (E) FISH image of an NCI-H660 interphase nucleus assessed by dual-color TMPRSS2 break-apart assay (as illustrated in A). The nucleus
contains a juxtaposed red and green signal for the wild-type allele, and a single green signal indicating the deletion of one centromeric red probe. This is indicative
of the fusion of TMPRSS2 with ERG through deletion of the intergenic region. (F) High-resolution FISH on chromatin fibers of NCI-H660 assessed by a TMPRSS2-
specific probe (RP11-121A5; red) and an ERG-specific probe (RP11-476D17; green) (as illustrated in Figure W1).
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ERG expression, and Meg01, a leukemia cell line with
known overexpression of the ERG oncogene, expresses
about 3000 times more ERG than PrSCs (Figure 1C). The
prostate carcinoma cell lines PC3, LNCaP, and DU145, and
the xenograft cell line 22Rv1 neither harbor TMPRSS2–ERG
fusion nor show high ERG expression levels (Figure 1C).
To confirm TMPRSS2–ERG rearrangement in the NCI-
H660 cell line, we used a two-stage dual-color break-apart
FISH assay testing first for TMPRSS2 and then for ERG
break-apart as indirect evidence for TMPRSS2–ERG fusion.
The indirect two-stage break-apart assessment is neces-
sary because both genes are located so close to each other
(a distance of only f 3 megabases) that a fusion cannot
be observed directly by a conventional FISH fusion assay.
Fusion through deletion of the region between TMPRSS2
and ERG is indicated by loss of the probes located be-
tween the two genes [3]. FISH assays for TMPRSS2 and
ERG break-apart are presented schematically in Figure 2A.
These assays demonstrated that NCI-H660 cells have bi-
allelic TMPRSS2–ERG fusion through genomic deletion
between TMPRSS2 and ERG on chromosome 21q22.2–3
(Figure 2, D and E ). The ERG break-apart assay showed
that on the centromeric side of the deletion, both telomeric
signals (probe 2, green; Figure 2A) are lost. The TMPRSS2
break-apart assay showed one centromeric signal (probe 3,
red; Figure 2A), consistent with one deletion reaching this
area and one deletion occurring at a more centromeric re-
gion. This observation of a homozygous genomic loss be-
tween TMPRSS2 and ERG on chromosome 21q22.2–3 has
important implications for using this cell line as a prostate
cancer model system, as no wild-type ERG allele is ex-
pressed. To date, we have observed one homozygous dele-
tion in over 300 fusion-positive prostate cancers (unpublished
observation). The fact that genomic deletions between ERG
and TMPRSS2 show different borders is in concordance with
our earlier observation that the deleted region is variable in
length [3]. For the first time, we were able to visualize the
fusion of TMPRSS2 and ERG on chromatin fibers of NCI-
H660 cells by a high-resolution fiber FISH approach [11]
using probes spanning specifically both loci (Figures 2F
and W1).
We then used oligonucleotide SNP arrays to further char-
acterize the NCI-H660 cell line and to compare it with other
cell lines, xenografts, and prostate cancer samples, including
Figure 3. Genomic loss between TMPRSS2 and ERG on chromosome 21q22.2–3 in prostate cancer cell lines, xenografts, and metastatic prostate cancer
samples. 8K SNP data on a panel of 25 prostate cancer samples revealed genomic deletion between TMPRSS2 and ERG (21q22.2–3) in a subset of samples. (A)
Twenty-five prostate cancer samples, including 7 cell lines, 11 xenografts, and 7 prostate cancer metastases, were analyzed for their TMPRSS2–ERG fusion
status by qPCR and/or FISH and color-coded as described before [3] (blue, fusion-negative; green, fusion-positive through translocation; orange, fusion-positive
through deletion). The plots on the right side of the panel represent the copy number ratio of the NCI-H660 and VCaP cell lines (vertical red lines represent
baseline; no copy number variation). It is evident that VCaP shows copy number gain throughout the whole q arm of chromosome 21. (B) Magnification of the black
framed box in (A), and status of the AR on chromosome X in these 25 samples. The blue signal in NCI-H660 corresponds to genomic copy number loss between
TMPRSS2 and ERG. The strong intensity of this signal is consistent with homozygous loss, as demonstrated by FISH. The boundaries of the intronic deletion of
NCI-H660 are very similar to the deletions seen in xenografts and tissue samples. Toward the telomeric side of the deletion in NCI-H660, the signal intensity is
weaker, confirming different lengths of the deletions seen by FISH. The androgen-independent NCI-H660 cell line shows a loss in the region of the AR, whereas
VCaP, which is known to be androgen-responsive, shows genomic gain in this area.
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hormone-naı¨ve and hormone-refractorymetastases (Figure 3,
A and B). We identified the loss of about three megabases of
genomic material on SNPs located between TMPRSS2 and
ERG in the NCI-H660 cell line with a strong loss of signal
intensity, corresponding to the homozygous deletion in these
cells that was detected by FISH (Figure 2, D and E). Toward
the telomeric side of the deletion in NCI-H660, the copy
number ratio increases, suggesting that one allele is present
in that area. This confirms the different lengths of the deletions
that were detected by FISH. For comparison, the VCaP cell
line showed significant copy number gain on chromosome21q
(Figure 3A). In agreement with SNP data, we found multiple
signals for both wild-type TMPRSS2 and wild-type ERG in
VCaP nuclei using independent TMPRSS2 and ERG break-
apart FISH assays (Figure 2, B and C). Therefore, we con-
clude that the copy number gain on chromosome 21 leads to
copy number gains of wild-type TMPRSS2 and ERG. Inter-
estingly, the two small cell prostate cancer xenografts included
in this study (LuCaP 49 and LuCaP 93) both showed
TMPRSS2–ERG rearrangement through genomic deletion
(denoted by * in Figure 3, A and B).
Because NCI-H660 is derived from an androgen-
independent small cell prostate tumor and was shown to be
negative for AR on both transcript and protein levels [18], we
also analyzed the AR locus on chromosome X for all samples
(Figure 3B). NCI-H660 had a loss in that region, as most of
the other xenografts and tissue samples in that panel. SNP
data confirmed the negative AR status of this cell line.
To investigate whether TMPRSS2–ERG fusion results in
the androgen regulation of ERG in AR-negative NCI-H660
cells, we assessed the expression of ERG by qPCR in
androgen-treated NCI-H660 and VCaP cells. The androgen-
sensitive VCaP cell line has been shown to respond to
androgen stimulation with increased ERG expression sen-
sitive to bicalutamide and flutamide [1] (Figure 4A). As ex-
pected, NCI-H660 does not respond to androgen stimulation
with increased expression of PSA or ERG, nor is it sensitive
to the AR antagonist flutamide (Figure 4B).
Discussion
A significant percentage of prostate cancers express a sig-
nature gene fusion of the 5V region of androgen-regulated
TMPRSS2 gene to an ETS family transcription factor, most
commonly the ERG gene. This is the first demonstration of
constitutive oncogene activation in prostate cancer. However,
the functional consequences of this chromosomal rearrange-
ment are difficult to predict and study. Reliable preclinical
in vitro models, which use homogenous human cellular ma-
terial that can be studied in large quantities over time, are
needed. The NCI-H660 cell line is a novel in vitro model
for prostate cancer that closely relates to the molecular sig-
nature of clinical cases. We demonstrate that NCI-H660 has
an intronic deletion on chromosome 21 that was found to be
the most common mechanism underlying TMPRSS2–ERG
fusion [3]. This deletion is observed on both alleles as a
homozygous loss. Therefore, NCI-H660 expresses neither
TMPRSS2 nor ERG in the native genomic context.
NCI-H660 does not express AR and is representative of
TMPRSS2–ERG–positive androgen-independent prostate
cancer. It has been shown that both TMPRSS2–ERG
fusion and the associated deletion occur in androgen-
independent prostate cancers and metastases that have no
functional AR [3]. The membrane-bound serine protease
TMPRSS2 can be expressed in both androgen-dependent
andandrogen-independent tumors (i.e., this usually androgen-
responsive gene can be uncoupled from androgen control)
[19]. Androgen-independent expression of TMPRSS2–ERG
in the NCI-H660 cell line is in line with this observation. NCI-
H660 as an androgen-independent model system might fa-
cilitate the search for androgen-independent factors and
pathways influencing TMPRSS2–ERG fusion. In contrast to
a recent report showing that TMPRSS2–ERG gene fusion is
not expressed in AR-negative prostate cancer specimens
[20], we and others [21] have found TMPRSS2–ERG and
ERG expression in the AR-negative NCI-H660 cell line. This
implies that TMPRSS2–ERG fusion is constitutively stimu-
lated in this androgen-independent prostate cancer cell line.
Further efforts will be directed at investigating which factors
can activate TMPRSS2–ERG fusion with subsequent ERG
overexpression, using the NCI-H660 cell line as an in vitro
model for TMPRSS2–ERG fusion through deletion.
In summary, the NCI-H660 cell line is a potent in vitro tool
with a genotypic profile that reflects the TMPRSS2–ERG
Figure 4. The androgen stimulation of the VCaP and NCI-H660 prostate
cancer cell lines carrying TMPRSS2–ERG fusion. PSA (red bars), ERG
(exons 5 and 6; dark blue bars), and TMPRSS–ERG (TMPRSS2 exon 1 to
ERG exon 4; light blue bars) expression relative to HMBS in androgen-
sensitive VCaP cells (A) and androgen-insensitive NCI-H660 cells (B) was
assessed by qPCR. Cell lines were incubated with vehicle or 10 M of the
AR antagonist flutamide for 2 hours before treatment for 24 hours with 0.5 or
5 nM of the synthetic androgen R1881 or vehicle, as indicated. Relative
amounts of PSA, ERG, or TMPRSS2–ERG per HMBS were compared for
VCaP and NCI-H660.
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rearrangement found in human prostate cancer. The NCI-
H660 cell line should be a valuable model for prostate cancer
and has the potential to provide important pathogenic insight
and guidance for therapeutic strategies.
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Figure W1. FISH on DNA fibers to map TMPRSS2–ERG fusion in the NCI-H660 cell line. FISH was conducted on preparations of extended chromatin fibers of
NCI-H660, resulting in a superior mapping resolution compared to interphase FISH. This is useful in mapping and assessing the relative length of adjacent DNA
fragments. (A–D) Stretched NCI-H660 DNA fibers were hybridized with probes specific to TMPRSS2 (RP11-120C17; red) and ERG (RP11-476D17; green). The
TMPRSS2 fusion partner is shorter relative to the ERG one (as seen from the illustration). Four representative pictures are shown. Immediately after exposure to
light, DNA fibers start breaking at many locations. From each break, the two free ends of DNA spring back to the nearest attachment point and coil, leaving a gap
between them. These ends resemble little beads and are thicker than the rest of the fiber. Therefore, DNA probes hybridize like arrays of dots (‘‘beads on a string’’).
